

Raoul Poupon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3407999/publications.pdf>

Version: 2024-02-01

95
papers

18,369
citations

10986
71
h-index

40979
93
g-index

96
all docs

96
docs citations

96
times ranked

11469
citing authors

#	ARTICLE	IF	CITATIONS
1	Primary biliary cirrhosis. Hepatology, 2009, 50, 291-308.	7.3	1,020
2	A Multicenter, Controlled Trial of Ursodiol for the Treatment of Primary Biliary Cirrhosis. New England Journal of Medicine, 1991, 324, 1548-1554.	27.0	709
3	Controlled Attenuation Parameter (CAP): A Novel VCTEâ„¢ Guided Ultrasonic Attenuation Measurement for the Evaluation of Hepatic Steatosis: Preliminary Study and Validation in a Cohort of Patients with Chronic Liver Disease from Various Causes. Ultrasound in Medicine and Biology, 2010, 36, 1825-1835.	1.5	683
4	Improved survival after variceal bleeding in patients with cirrhosis over the past two decades. Hepatology, 2004, 40, 652-659.	7.3	681
5	Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases. Gut, 2013, 62, 531-539.	12.1	663
6	Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: Clinical features and response to therapy. Hepatology, 1998, 28, 296-301.	7.3	633
7	Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: A second type of "autoimmune" hepatitis. Hepatology, 1987, 7, 1333-1339.	7.3	571
8	Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology, 2008, 48, 871-877.	7.3	552
9	Ursodiol for the Long-Term Treatment of Primary Biliary Cirrhosis. New England Journal of Medicine, 1994, 330, 1342-1347.	27.0	467
10	Noninvasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B. Liver International, 2009, 29, 242-247.	3.9	432
11	Hypoxia-induced VEGF and collagen I expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis. Hepatology, 2002, 35, 1010-1021.	7.3	416
12	New paradigms in the treatment of hepatic cholestasis: From UDCA to FXR, PXR and beyond. Journal of Hepatology, 2015, 62, S25-S37.	3.7	406
13	Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC. Hepatology, 2006, 43, 1118-1124.	7.3	401
14	A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis. New England Journal of Medicine, 2018, 378, 2171-2181.	27.0	383
15	Levels of Alkaline Phosphatase and Bilirubin Are Surrogate End Points of Outcomes of Patients With Primary Biliary Cirrhosis: An International Follow-up Study. Gastroenterology, 2014, 147, 1338-1349.e5.	1.3	365
16	Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology, 1998, 27, 1435-1440.	7.3	359
17	Early primary biliary cirrhosis: Biochemical response to treatment and prediction of long-term outcome. Journal of Hepatology, 2011, 55, 1361-1367.	3.7	353
18	Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: Effect of ursodeoxycholic acid. Hepatology, 1990, 11, 12-15.	7.3	313

#	ARTICLE	IF	CITATIONS
19	MDR3 gene defect in adults with symptomatic intrahepatic and gallbladder cholesterol cholelithiasis. Gastroenterology, 2001, 120, 1459-1467.	1.3	309
20	Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis. Hepatology, 2005, 41, 307-314.	7.3	308
21	A Randomized Controlled Study of Propranolol for Prevention of Recurrent Gastrointestinal Bleeding in Patients with Cirrhosis: A Final Report. Hepatology, 1984, 4, 355-358.	7.3	292
22	Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C. Journal of Hepatology, 2001, 34, 428-434.	3.7	289
23	Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis. Hepatology, 2012, 56, 198-208.	7.3	277
24	ABCB4 gene mutation-associated cholelithiasis in adults. Gastroenterology, 2003, 125, 452-459.	1.3	267
25	The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology, 2000, 32, 1196-1199.	7.3	265
26	Primary biliary cirrhosis: A 2010 update. Journal of Hepatology, 2010, 52, 745-758.	3.7	251
27	Diffusion-weighted magnetic resonance imaging for the assessment of fibrosis in chronic hepatitis C. Hepatology, 2007, 46, 658-665.	7.3	244
28	Features associated with success rate and performance of fibroscan measurements for the diagnosis of cirrhosis in HCV patients: A prospective study of 935 patients. Journal of Hepatology, 2007, 46, 628-634.	3.7	227
29	Chronic liver injury during obstructive sleep apnea. Hepatology, 2005, 41, 1290-1296.	7.3	221
30	The Myofibroblastic Conversion of Peribiliary Fibrogenic Cells Distinct from Hepatic Stellate Cells Is Stimulated by Platelet-Derived Growth Factor During Liver Fibrogenesis. Laboratory Investigation, 2003, 83, 163-173.	3.7	206
31	A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis. Hepatology, 2018, 67, 1890-1902.	7.3	204
32	Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis. Journal of Hepatology, 2003, 39, 12-16.	3.7	199
33	Demographic, lifestyle, medical and familial factors associated with primary biliary cirrhosis. Journal of Hepatology, 2010, 53, 162-169.	3.7	197
34	Hepatocellular Hypoxia-Induced Vascular Endothelial Growth Factor Expression and Angiogenesis in Experimental Biliary Cirrhosis. American Journal of Pathology, 1999, 155, 1065-1073.	3.8	189
35	Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. Hepatology, 1999, 29, 1668-1671.	7.3	184
36	Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. Journal of Hepatology, 2006, 44, 400-406.	3.7	181

#	ARTICLE	IF	CITATIONS
37	Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: An overview of their mechanisms of action. Clinics and Research in Hepatology and Gastroenterology, 2012, 36, S3-S12.	1.5	177
38	Impact of steatosis on progression of fibrosis in patients with mild hepatitis C. Hepatology, 2005, 41, 82-87.	7.3	169
39	Ursodeoxycholic acid for primary sclerosing cholangitis. Journal of Hepatology, 1990, 11, 120-123.	3.7	164
40	Histopathological study of primary biliary cirrhosis and the effect of ursodeoxycholic acid treatment on histology progression. Hepatology, 1999, 29, 1007-1012.	7.3	162
41	Development of autoimmune hepatitis in patients with typical primary biliary cirrhosis. Hepatology, 2006, 44, 85-90.	7.3	153
42	Differential effects of chenodeoxycholic and ursodeoxycholic acids on interleukin 1, interleukin 6 and tumor necrosis factor- α production by monocytes. Hepatology, 1992, 16, 719-723.	7.3	139
43	Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study. Gut, 2016, 65, 321-329.	12.1	139
44	PDGF-Mediated Chemoattraction of Hepatic Stellate Cells by Bile Duct Segments in Cholestatic Liver Injury. Laboratory Investigation, 2000, 80, 697-707.	3.7	131
45	Non-organ specific autoantibodies associated with chronic C virus hepatitis. Journal of Hepatology, 1993, 18, 359-364.	3.7	127
46	A modified international normalized ratio as an effective way of prothrombin time standardization in hepatology. Hepatology, 2007, 46, 528-534.	7.3	123
47	Serum adipokine levels predictive of liver injury in non-alcoholic fatty liver disease. Liver International, 2009, 29, 1431-1438.	3.9	121
48	Serum bile acids in primary biliary cirrhosis: Effect of ursodeoxycholic acid therapy. Hepatology, 1993, 17, 599-604.	7.3	118
49	Quality of life in patients with primary biliary cirrhosis. Hepatology, 2004, 40, 489-494.	7.3	118
50	Chronic Hepatitis B Virus Carriers in the Immunotolerant Phase of Infection: Histologic Findings and Outcome. Clinical Gastroenterology and Hepatology, 2007, 5, 636-641.	4.4	118
51	Preventive therapy of first gastrointestinal bleeding in patients with cirrhosis: Results of a controlled trial comparing propranolol, endoscopic sclerotherapy and placebo. Hepatology, 1990, 12, 1413-1419.	7.3	115
52	Genetic factors of susceptibility and of severity in primary biliary cirrhosis. Journal of Hepatology, 2008, 49, 1038-1045.	3.7	115
53	Serum hyaluronan as a marker of liver fibrosis in chronic viral hepatitis C: effect of α -interferon therapy. Journal of Hepatology, 1995, 22, 22-26.	3.7	113
54	Impact of IGF-1R/EGFR cross-talks on hepatoma cell sensitivity to gefitinib. International Journal of Cancer, 2006, 119, 2557-2566.	5.1	113

#	ARTICLE	IF	CITATIONS
55	Drug-induced hepatitis associated with anticytoplasmic organelle autoantibodies. Hepatology, 1985, 5, 722-727.	7.3	107
56	Immunosuppressive properties of chenodeoxycholic and ursodeoxycholic acids in the mouse. Gastroenterology, 1992, 103, 617-621.	1.3	107
57	Genotype-phenotype relationships in the low-phospholipid-associated cholelithiasis syndrome: A study of 156 consecutive patients. Hepatology, 2013, 58, 1105-1110.	7.3	105
58	Factors predictive of the response to interferon in patients with chronic hepatitis C. Journal of Hepatology, 1994, 21, 12-17.	3.7	98
59	Hepatic Stellate Cell Proliferation is an Early Platelet-Derived Growth Factor-Mediated Cellular Event in Rat Cholestatic Liver Injury. Laboratory Investigation, 2001, 81, 1709-1716.	3.7	95
60	Prognostic value of serum hyaluronan in patients with compensated HCV cirrhosis. Journal of Hepatology, 2000, 32, 447-452.	3.7	93
61	Large-scale characterization study of patients with antimitochondrial antibodies but nonestablished primary biliary cholangitis. Hepatology, 2017, 65, 152-163.	7.3	93
62	Relationship between procollagen III aminoterminal propeptide and hyaluronan serum levels and histological fibrosis in primary biliary cirrhosis and chronic viral hepatitis C. Journal of Hepatology, 1994, 20, 388-393.	3.7	89
63	Disease activity and cancer risk in inflammatory bowel disease associated with primary sclerosing cholangitis. World Journal of Gastroenterology, 2008, 14, 3497.	3.3	87
64	Preventive administration of UDCA after liver transplantation for primary biliary cirrhosis is associated with a lower risk of disease recurrence. Journal of Hepatology, 2015, 63, 1449-1458.	3.7	84
65	Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: A prospective magnetic resonance imaging and histological study. Hepatology, 2009, 50, 528-537.	7.3	83
66	Effect of The Interaction Between Steatosis and Alcohol Intake on Liver Fibrosis Progression in Chronic Hepatitis C. American Journal of Gastroenterology, 2002, 97, 1807-1812.	0.4	82
67	Amoxicillin-clavulanic acid therapy of spontaneous bacterial peritonitis: A prospective study of twenty-seven cases in cirrhotic patients. Hepatology, 1990, 11, 360-364.	7.3	80
68	Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone: Results of a pilot study. Hepatology, 2001, 34, 573-577.	7.3	78
69	Clinical and biochemical expression of the histopathological lesions of primary biliary cirrhosis. Journal of Hepatology, 1999, 30, 408-412.	3.7	77
70	Fetal microchimerism in primary biliary cirrhosis. Journal of Hepatology, 2000, 33, 696-700.	3.7	77
71	Hepatocyte Growth Factor and c-Met Inhibition by Hepatic Cell Hypoxia. American Journal of Pathology, 2002, 160, 613-620.	3.8	76
72	Liver alkaline phosphatase: A missing link between cholestasis and biliary inflammation. Hepatology, 2015, 61, 2080-2090.	7.3	76

#	ARTICLE	IF	CITATIONS
73	Aspects of liver pathology in adult patients with MDR3/ABCB4 gene mutations. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2012, 460, 291-298.	2.8	69
74	Autoimmune overlapping syndromes. Clinics in Liver Disease, 2003, 7, 865-878.	2.1	64
75	Shaping macrophages function and innate immunity by bile acids: Mechanisms and implication in cholestatic liver diseases. Clinics and Research in Hepatology and Gastroenterology, 2014, 38, 550-556.	1.5	63
76	Bile acids modulate the interferon signalling pathway. Hepatology, 1999, 29, 1840-1847.	7.3	53
77	Cholestasis induces major histocompatibility complex class I expression in hepatocytes. Gastroenterology, 1992, 102, 1371-1377.	1.3	48
78	Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis. Journal of Hepatology, 2020, 73, 559-565.	3.7	47
79	Primary sclerosing cholangitis response to the combination of fibrates with ursodeoxycholic acid: French-Spanish experience. Clinics and Research in Hepatology and Gastroenterology, 2018, 42, 521-528.	1.5	40
80	Effect of cholestasis and bile acids on interferon-induced 2'5'-adenylate synthetase and NK cell activities. Gastroenterology, 1995, 108, 1192-1198.	1.3	38
81	Combined features of low phospholipid-associated cholelithiasis and progressive familial intrahepatic cholestasis 3. Liver International, 2010, 30, 327-331.	3.9	35
82	Intrahepatic cholestasis of pregnancy: from bedside to bench to bedside. Liver International, 2005, 25, 467-468.	3.9	28
83	Changing nomenclature for PBC: from "cirrhosis" to "cholangitis". Gut, 2015, 64, 1671-1672.	12.1	28
84	Immune response to lipopolysaccharide in primary biliary cirrhosis and autoimmune diseases. Journal of Autoimmunity, 2004, 22, 153-158.	6.5	27
85	Low-phospholipid-associated cholelithiasis syndrome: Prevalence, clinical features, and comorbidities. JHEP Reports, 2021, 3, 100201.	4.9	24
86	New treatments/targets for primary biliary cholangitis. JHEP Reports, 2019, 1, 203-213.	4.9	17
87	ASBT inhibitors in cholangiopathies " Good for mice, good for men?. Journal of Hepatology, 2016, 64, 537-538.	3.7	13
88	Inhibition of procoagulant activity of human monocytes by chenodeoxycholic acid: Involvement of protein kinase C. Hepatology, 1994, 19, 1164-1170.	7.3	12
89	Differential effects of chenodeoxycholic and ursodeoxycholic acids on expression of procoagulant activity by human monocytes. Journal of Hepatology, 1994, 20, 466-472.	3.7	12
90	Effects of bile acids on the humoral immune response A mechanistic approach. Life Sciences, 2001, 69, 2337-2348.	4.3	12

#	ARTICLE	IF	CITATIONS
91	Antipruritic effect of bezafibrate and serum autotaxin measures in patients with primary biliary cholangitis. Gut, 2019, 68, 1902-1903.	12.1	10
92	Fenofibrate-induced massive regression of multiple inflammatory hepatocellular adenoma. Clinics and Research in Hepatology and Gastroenterology, 2016, 40, e1-e3.	1.5	6
93	Serum proteomic signatures as biomarkers of primary biliary cirrhosis diagnosis and prognosis. Annales De Biologie Clinique, 2016, 74, 607-612.	0.1	4
94	Treatment of primary biliary cirrhosis. Expert Opinion on Orphan Drugs, 2014, 2, 11-25.	0.8	0
95	Therapeutics Highlights from ILC 2018, the EASL annual congress. Clinics and Research in Hepatology and Gastroenterology, 2018, 42, 294-295.	1.5	0